International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.

BACKGROUND Analysis of candidate genes in individual studies has had only limited success in identifying particular gene variants that are conclusively associated with lung cancer risk. In the International Lung Cancer Consortium (ILCCO), we conducted a coordinated genotyping study of 10 common variants selected because of their prior evidence of an association with lung cancer. These variants belonged to candidate genes from different cancer-related pathways including inflammation (IL1B), folate metabolism (MTHFR), regulatory function (AKAP9 and CAMKK1), cell adhesion (SEZL6) and apoptosis (FAS, FASL, TP53, TP53BP1 and BAT3). METHODS Genotype data from 15 ILCCO case-control studies were available for a total of 8431 lung cancer cases and 11 072 controls of European descent and Asian ethnic groups. Unconditional logistic regression was used to model the association between each variant and lung cancer risk. RESULTS Only the association between a non-synonymous variant of TP53BP1 (rs560191) and lung cancer risk was significant (OR = 0.91, P = 0.002). This association was more striking for squamous cell carcinoma (OR = 0.86, P = 6 x 10(-4)). No heterogeneity by center, ethnicity, smoking status, age group or sex was observed. In order to confirm this association, we included results for this variant from a set of independent studies (9966 cases/11,722 controls) and we reported similar results. When combining all these studies together, we reported an overall OR = 0.93 (0.89-0.97) (P = 0.001). This association was significant only for squamous cell carcinoma [OR = 0.89 (0.85-0.95), P = 1 x 10(-4)]. CONCLUSION This study suggests that rs560191 is associated to lung cancer risk and further highlights the value of consortia in replicating or refuting published genetic associations.

[1]  Ying Wang,et al.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. , 2009, American journal of human genetics.

[2]  M. Karagas,et al.  Lung Cancer in a U.S. Population with Low to Moderate Arsenic Exposure , 2009, Environmental health perspectives.

[3]  S. Zienolddiny,et al.  A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. , 2009, Carcinogenesis.

[4]  P. Brennan,et al.  Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. , 2009, Cancer letters.

[5]  S. Zienolddiny,et al.  A specific interleukin-1 B haplotype correlates with high levels of IL 1 B mRNA in the lung and increased risk of non-small cell lung cancer , 2009 .

[6]  J. Kładny,et al.  Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology , 2009, Breast Cancer Research and Treatment.

[7]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[8]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[9]  Y. Matsumoto,et al.  Characterization of a cancer cell line that expresses a splicing variant form of 53BP1: separation of checkpoint and repair functions in 53BP1. , 2008, Biochemical and biophysical research communications.

[10]  Xihong Lin,et al.  Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. , 2008, Carcinogenesis.

[11]  Paolo Vineis,et al.  International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. , 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  Weiwei Sun,et al.  Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. , 2008, Lung cancer.

[13]  S. Wacholder,et al.  Environment And Genetics in Lung cancer Etiology (EAGLE) study: An integrative population-based case-control study of lung cancer , 2008, BMC public health.

[14]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[15]  Florian Kronenberg,et al.  Matrix Metalloproteinase 1 (MMP1) Is Associated with Early-Onset Lung Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[17]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[18]  J. Bai,et al.  Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis , 2008, Journal of Human Genetics.

[19]  John K Field,et al.  Seizure 6-like (SEZ6L) gene and risk for lung cancer. , 2007, Cancer research.

[20]  K. Matsuo,et al.  Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. , 2007, Carcinogenesis.

[21]  Wei Zhang,et al.  Polymorphic TP53BP1 and TP53 Gene Interactions Associated with Risk of Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[22]  M. Spitz,et al.  Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. , 2007, Cancer research.

[23]  P. Brennan,et al.  Folate-related genes and the risk of tobacco-related cancers in Central Europe. , 2007, Carcinogenesis.

[24]  Yun-Chul Hong,et al.  Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. , 2007, Lung cancer.

[25]  A. N. Hicks,et al.  The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  Dong Sun Kim,et al.  Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. , 2006, Lung cancer.

[27]  P. Brennan,et al.  Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. , 2006, Cancer research.

[28]  T. Eisen,et al.  Variants in the GH-IGF axis confer susceptibility to lung cancer. , 2006, Genome research.

[29]  D. Campa,et al.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.

[30]  H. Morgenstern,et al.  Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus , 2006, International journal of cancer.

[31]  Robert N Hoover,et al.  Methods for etiologic and early marker investigations in the PLCO trial. , 2005, Mutation research.

[32]  W. Tan,et al.  [Association between genetic polymorphisms in methylentetrahydrofolate reductase and risk of lung cancer]. , 2005, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[33]  T. Eisen,et al.  Systematic review of the relationship between family history and lung cancer risk , 2005, British Journal of Cancer.

[34]  N. Rothman,et al.  Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. , 2005, Lung cancer.

[35]  M. Spitz,et al.  Sex Differences in Risk of Lung Cancer Associated with Methylene-tetrahydrofolate Reductase Polymorphisms , 2005, Cancer Epidemiology Biomarkers & Prevention.

[36]  W. Tan,et al.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer , 2005, Journal of Medical Genetics.

[37]  W. Tan,et al.  [Association of two genetic polymorphisms in the 5'untranslated region of exon 2 of the p73 gene and risk of lung cancer]. , 2005, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[38]  Bin Zhao,et al.  CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: influence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation , 2005, Cancer Causes & Control.

[39]  D. Gudbjartsson,et al.  Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family , 2004, PLoS medicine.

[40]  Marshall W. Anderson,et al.  A major lung cancer susceptibility locus maps to chromosome 6q23-25. , 2004, American journal of human genetics.

[41]  F. Canzian,et al.  Polymorphisms of the interleukin‐1 β gene are associated with increased risk of non‐small cell lung cancer , 2004, International journal of cancer.

[42]  Chien-Jen Chen,et al.  The methylenetetrahydrofolate reductase 677C-->T polymorphism and lung cancer risk in a Chinese population. , 2003, Anticancer research.

[43]  J. Gmiński,et al.  Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. , 2003, Oncology reports.

[44]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[45]  K. Czene,et al.  Attributable risks of familial cancer from the Family-Cancer Database. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  M. Spitz,et al.  p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. , 2002, Journal of the National Cancer Institute.

[47]  M. Thun,et al.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.

[48]  Junjie Chen,et al.  Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage–Signaling Pathways , 2001, The Journal of cell biology.

[49]  Hongbing Shen,et al.  Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[50]  N. Rothman,et al.  Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: a case-control study in Xuan Wei, China. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  L. Marchand,et al.  Relationships of TP 53 Codon 72 and HRAS 1 Polymorphisms with Lung Cancer Risk in an Ethnically Diverse Population 1 , 2000 .

[52]  Bin Li,et al.  Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2* , 1998, The Journal of Biological Chemistry.

[53]  R. Birgander,et al.  P53 polymorphisms and haplotypes in lung cancer. , 1995, Carcinogenesis.

[54]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[55]  G. Omenn,et al.  The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. , 1994, Cancer research.

[56]  The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. , 1994, Annals of epidemiology.